secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001558370-23-015770
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP issues negative opinion on Translarna full authorization; PTC to seek re-examination
--------------------------------------------------------------------------------

- CHMP gave negative opinion on converting Translarna's conditional MA to full MA for nmDMD.
- Negative opinion also applies to renewal of existing conditional authorization.
- PTC will submit re-examination request; expected CHMP opinion in Jan 2024, EC ratification within 67 days.
- Translarna stays on market for nmDMD patients during re-examination process.
- PTC cites favorable safety profile & efficacy data from 3 placebo-controlled trials and STRIDE registry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837023015770/0001558370-23-015770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837023015770/tmb-20230915x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer